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Abstract 
Background: Tumour‑derived exosomes can be released to serum and provide information on the features of the 
malignancy, however, in order to perform systematic studies in biological samples, faster diagnostic techniques are 
needed, especially for detection of low abundance proteins. Most human cancer cells are positive for at least one 
ligand for the activating immune receptor NKG2D and the presence in plasma of NKG2D‑ligands can be associated 
with prognosis.
Methods: Using MICA as example of a tumour‑derived antigen, endogenously expressed in metastatic melanoma 
and recruited to exosomes, we have developed two immunocapture‑based assays for detection of different epitopes 
in nanovesicles. Although both techniques, enzyme‑linked immunosorbent assay (ELISA) and Lateral flow immunoas‑
says (LFIA) have the same theoretical basis, that is, using capture and detection antibodies for a colorimetric read‑out, 
analysis of exosome‑bound proteins poses methodological problems that do not occur when these techniques are 
used for detection of soluble molecules, due to the presence of multiple epitopes on the vesicle.
Results: Here we demonstrate that, in ELISA, the signal obtained was directly proportional to the amount of epitopes 
per exosome. In LFIA, the amount of detection antibody immobilized in Au‑nanoparticles needs to be low for efficient 
detection, otherwise steric hindrance results in lower signal. We describe the conditions for detection of MICA in 
exosomes and prove, for the first time using both techniques, the co‑existence in one vesicle of exosomal markers 
(the tetraspanins CD9, CD63 and CD81) and an endogenously expressed tumour‑derived antigen. The study also 
reveals that scarce proteins can be used as targets for detection antibody in LFIA with a better result than very abun‑
dant proteins and that the conditions can be optimized for detection of the protein in plasma.
Conclusions: These results open the possibility of analyzing biological samples for the presence of tumour‑derived 
exosomes using high throughput techniques.
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Background
Normal cells release a variety of small sized vesicles, 
called extracellular vesicles (EVs) with different origins, 
size and composition [1–3]. Exosomes are a subtype of 
EVs that originate after fusion of subcellular organelles 
with the plasma membrane and release of the small 
intraluminal vesicles. These vesicles usually have a diam-
eter of 50–150 nm and are enriched in markers from the 
endocytic pathway and tetraspanins such as CD63, CD9 
and CD81. Exosomes carry different types of molecules 
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including nucleic acids and proteins that can transfer 
information between different cells. Specific molecules 
are actively recruited to exosomes using different tar-
geting methods, for example, miRNAs are included in 
exosomes when they carry a particular motif [4, 5] and 
proteins with a fatty acid or GPI modification are also 
more commonly found in these vesicles [6, 7]. The par-
ticular lipid composition of the exosome membrane may 
also contribute to the recruitment of specific biomol-
ecules [8].
Exosomes can be found in many biological fluids, like 
plasma, urine, saliva and interstitial liquid of healthy 
donors and patients, but their roles in human physiol-
ogy are largely unknown [9]. However, because only cer-
tain cellular molecules are incorporated into exosomes, 
analysis of the composition of these nanovesicles can 
provide significant information about the cell of origin. 
Thus, there is great interest in developing methods for 
the detection of biomolecules contained in exosomes 
and to explore the possibility of using them as a tool for 
diagnosis.
Exosomes are released in large quantities from cer-
tain tumour cells and tumour-derived exosomes can be 
detected in patient biological fluids [10], therefore, their 
analysis can provide information about the cell that origi-
nated the vesicles. For example, exosomes from mela-
noma cell lines contain tumour antigens such as Mart-1/
MelanA [11–13]. In addition, tumour-derived exosomes 
have been also shown to contain molecules with immune 
modulation properties, such as apoptosis induction by 
FasL, TRAIL, PD-L1 [14], immune suppression through 
TGFβ [15], or antigen cross-presentation [11, 13].
A paradigm of a molecule released by tumour cells with 
immune modulation functions is MICA (MHC class I 
chain-related protein A), a protein belonging to stress-
related molecules that bind to the activating immune 
receptor NKG2D (activating natural killer group 2D) 
expressed on all human NK and  CD8+ T cells [16]. Sol-
uble ligands for NKG2D, including MICA, have been 
found in serum from several types of cancer patients and, 
in humans, high levels of soluble NKG2D ligands gener-
ally correlate with higher tumor grade and worse prog-
nosis [17]. Indeed, it has recently been shown that the 
presence of soluble NKG2D-ligands influences the clini-
cal outcome of cancer patients treated with checkpoint-
inhibitor monoclonal antibodies [18]. Similarly, the use 
of antibodies against the α3 domain of MICA to decrease 
the release of ligand also promotes tumour immunity 
[19]. We have previously described that certain NKG2D-
ligands are recruited into exosome fractions and that they 
are potent modulators of the immune response [20, 21]. 
In fact, membrane-bound NKG2D-ligands downmodu-
late the receptor more efficiently than metalloprotease 
cleaved soluble species [22, 23]. Thus, it is very likely that 
the study of NKG2D-ligands contained in exosomes of 
biological fluids will shed light on the modulation of the 
immune response in cancer patients.
Since current protocols for exosome analysis often 
require expensive equipment and specialist knowledge 
[3], we aimed to develop new tools for detection of the 
tumour-derived protein MICA in exosomes, using meth-
ods based on immunocapture of tetraspanins, as gen-
eral exosome markers, coupled with detection of MICA. 
Since different exosome populations can have different 
content of tetraspanins [24], we first defined different 
antibody combinations, for either detection or capture 
of vesicles, that could be used in enzyme-linked immu-
nosorbent assay (ELISA), an immunological method that 
firstly immobilises the target antigen using a capture 
antibody followed by detection using a second, labelled-
antibody. Using this technique, we demonstrate here for 
the first time the presence of MICA in vesicles containing 
CD9, CD63 or CD81.
We have previously shown that exosomes can be 
detected in lateral flow immunoassays (LFIA) using com-
binations of tetraspanin-specific mAbs [25]. This tech-
nique has the same conceptual basis as ELISA, however, 
in a first step, samples are mixed with detection antibody, 
previously attached to gold nanoparticles (AuNP) for 
visualization, and then the mixture is allowed to reach 
by capillarity a line of capture antibody recognizing a dif-
ferent epitope. While optimizing LFIA for detection of 
MICA-containing exosomes, we have discovered that the 
difference in the experimental set up between ELISA and 
LFIA can markedly affect the outcome of the experiment, 
because exosomes contain multiple epitopes of each tar-
get per vesicle both for capture and detection antibod-
ies, and this can affect multimerization and aggregation. 
In fact, we demonstrate that abundant proteins should 
not be used as targets for a detection antibody in LFIA 
because, in this case, steric impediments on the limited 
surface area of exosomes can impair binding of the sec-
ond capture antibody.
Results
Melanoma‑derived exosomes express the endogenous 
stress‑related molecule MICA
As a first step in the development of new antibody 
combinations to detect and analyse the composition of 
tumour-derived exosomes, nanovesicles isolated from 
tissue culture supernatant of the metastatic melanoma 
cell line, Ma-Mel-86c, were characterized. Nanosight 
analysis revealed that the size of the melanoma-derived 
exosomes was on average around 120  nm and this was 
confirmed by electron microscopy (Fig. 1a). The expres-
sion of widely expressed exosome markers, such as the 
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tetraspanins CD9, CD81 and CD63, was verified by 
Western blot in the preparation of exosomes from the 
same cell line, Ma-Mel-86c (Fig. 1b). We have previously 
described that the metastatic melanoma cell line Ma-
Mel-86c expresses the NKG2D-ligand MICA at the cell 
surface and that the products of particular alleles of this 
gene are found in fractions in which exosome markers 
were also detected [7, 26]. As shown, endogenous MICA 
was present in melanoma-derived nanovesicles, but was 
much less abundant than tetraspanins. Nevertheless, 
when melanoma-derived exosomes were co-cultured 
with NK cells, the NKG2D receptor was downmodulated 
from NK cell surface, demonstrating that endogenously 
expressed MICA is exposed on the exosome surface and 
that it is biologically functional (Fig. 1c).
MICA can be detected by ELISA on tumour‑derived 
exosomes
Once the exosomes from the melanoma cell line Ma-
Mel-86c had been characterized phenotypically and 
functionally, the expression of MICA within these nan-
ovesicles was analysed by ELISA. It is important to 
remember here that exosomes are heterogeneous in their 
protein composition and that WB analyses can only dem-
onstrate co-fractionation of two markers, but cannot pro-
vide evidence for the coexistence of two proteins in the 
same particle. So, to prove that tetraspanins and MICA 
are present in the same vesicle, ELISA experiments were 
performed using combinations of antibodies against the 
different molecules (Fig. 2). Capture with anti-MICA and 
detection with anti-CD9 was a very efficient combination 
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Fig. 1 Characterization of exosomes from metastatic melanoma cell lines. Exosomes from Ma‑Mel‑86c cells were purified from tissue culture 
supernatant by ultracentrifugation. a TEM. Exosomes were analyzed by electron microscopy. Bar: 100 nm. b Western blot. MICA and tetraspanins 
(CD63, CD81 and CD9) were analysed by Western blot. Actin was used as loading control. The result from a representative experiment is shown. 
An exposure of 10–15 s is shown in the right panel. c NKG2D downmodulation. Activated NK cells were co‑incubated with increasing amounts of 
Ma‑Mel‑86c exosomes as indicated. Cells were stained with anti‑NKG2D and analysed by flow cytometry. The plot represents the change in the 
mean fluorescence intensity (MFI) of NKG2D on NK cells after incubation with exosomes, related to NK cells incubated in medium alone. Data are 
the mean and SEM obtained in three experiments using NK cells from different donors (*P < 0.05)
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Fig. 2 Detection of MICA‑containing exosomes by ELISA, using 
different tetraspanin‑specific antibodies. Different amounts of 
metastatic melanoma Ma‑Mel‑86c (86c) derived exosomes were 
analyzed by ELISA using the combinations of capture/detection 
antibodies indicated at the top of each plot (capture/detection). The 
plots represent the optical density (OD) at 405 nm. Negative controls 
(Blank) include capture and detection antibodies but no exosomes. 
Data are the mean and SEM of three independent experiments run in 
duplicates (*P < 0.05, **P < 0.01)
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for an ELISA platform. The opposite orientation, i.e. cap-
ture with tetraspanin (CD9 or CD63) and detection with 
anti-MICA also provided positive readings although the 
sensitivity was clearly less. Since the amount of MICA is 
relatively low in these exosomes, when compared to the 
amount of tetraspanin, it seems likely that the capture of 
the exosome through MICA allows a better amplification 
of the readout signal detecting a very abundant tetraspa-
nin like CD9.
Exosomal MICA can be detected by LFIA
Next, since we have already demonstrated that exosomes 
can be detected using LFIA devices [25], experiments to 
choose the best antibody combination for the develop-
ment of a new LFIA tool for the detection of MICA in 
exosomes were performed (Table 1 and Additional file 1: 
Figure  1A). MICA expression on melanoma-derived 
exosomes could be detected by LFIA using anti-CD9 for 
capture and anti-MICA for detection. Surprisingly, there 
was no positive signal when anti-MICA was used as cap-
ture antibody and either of the anti-tetraspanins (CD9 or 
CD63) antibodies were used for detection. This was also 
true when CD63 or CD81-specific antibodies were used 
for capture and anti-MICA for detection. Since these 
results differed markedly from the results of the ELISA 
platform, in which all combinations gave a positive result, 
we inferred that antibody recognition of the epitope was 
not a problem. We hypothesized that incubation of the 
different antibodies in solution in the first step of LFIA 
could generate steric hindrance affecting the outcome of 
the experiment, as we had previously speculated [25].
Since further optimization of the LFIA platform 
for exosome recognition of proteins was required, we 
assayed the effects of various modifications to the proto-
col, including the addition of different concentrations of 
the detergent Tween-20 or ethanol to the running buffer, 
the use of increasing concentrations of anti-MICA anti-
body, the inclusion of a pre-incubation step of detection 
antibody to exosomes and performing the assay in two 
steps (first running the exosomes and then the detec-
tion antibody) (Additional file 1: Figure 1B, C, D). These 
experiments defined the optimal basic assay conditions: 
using 0.05% Tween-20 in running buffer, 20 µL of AuNP 
coupled to anti-MICA detection antibody (prepared as 
explained in the “Methods” section) and pre-incubating 
exosomes with detection antibody for 1 h.
Next, to define the specificity, limits of detection 
and saturation properties of the assay, the amounts of 
exosomes from two different metastatic melanoma cell 
lines, Ma-Mel-86c and Ma-Mel-55, were titrated (Fig. 3a). 
The signal was quantified using a non-biased electronic 
tool and saturation curves were obtained (Fig. 3b). As a 
control of the assay specificity, a high concentration of 
exosomes from the bladder cell line RT112, devoid of 
MICA (Fig. 3c) were assayed in parallel producing no sig-
nal on the test line (depicted as a triangle in Fig. 3b). Sur-
prisingly, quantitative analysis of the MICA-containing 
exosomes from the melanomas yielded some interesting 
results: the signal from Ma-Mel-55 exosomes was higher 
than that of Ma-Mel-86c exosomes and reached a plateau 
at lower exosome  concentration (Fig.  3b), even though 
the amounts of MICA and CD9 protein in the exosome 
preparation from Ma-Mel-55 were lower than in Ma-
Mel-86c, when compared by Western blot (Fig. 3c). This 
observation, together with the fact that several combina-
tions of antibodies that worked well in ELISA were less 
efficient for detection in LFIA, led us to hypothesize 
that if the protein being detected is very abundant, the 
exosomes may become completely covered by the detec-
tion antibody (always used in excess so that it is available 
for capture in the control line, for flow validation of the 
test, after binding to the antigen). In these circumstances, 
steric hindrance probably makes the second epitope 
of the exosome inaccessible for capture in the test line 
(Fig. 3d). This model is also supported by data obtained 
using as detection antibody CD9 in combination with 
either CD63 or CD81 for capture  (Data not shown and 
[25]).
Optimization of LFIA for protein detection on exosomes 
requires low antibody concentration in the gold 
nanoparticles
The unexpected results with exosomes containing dif-
ferent amounts of MICA, apparently due to steric issues 
and the observation that the sample pads acquired col-
our from the gold nanoparticles, increasing with the 
pre-incubation time and with the number of exosomes 
(Additional file  1: Figure  2A, B), prompted new experi-
ments to check whether the evaluation of exosomes by 
LFIA was affected by the formation of nanoparticle com-
plexes which could alter the flow of the exosome sample 
in the strip. For this purpose, the concentration of anti-
MICA antibody conjugated to AuNP was reduced, try-
ing to couple four times less antibody per AuNP. NP with 
low amounts of coupled antibody were then compared 
Table 1 Combination of antibodies used for LFIA
25 corresponds to the reference list (Oliveria‑Rodríguez et al. [25])
ND, not determined; −, negative signal; +, positive signal
Detection antibody Capture antibody
MICA CD63 CD81 CD9
MICA ND – – +
CD63 – ND 25 25
CD9 – – 25 ND
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with NP with the maximal antibody conjugation (Fig. 4a, 
b). Interestingly, MICA was detected seven times better 
when AuNP with limited amounts of antibody on their 
surface were used. Moreover, analysis of the hydrody-
namic diameter using Dynamic Light Scattering (DLS) 
revealed that, if AuNP were saturated with antibody, the 
incubation with exosomes results in several peaks cor-
responding to aggregates of different sizes, while AuNP 
with limiting amounts of antibody displayed a uniform 
peak, with no evidence of aggregate formation (Fig. 4c).
Taken together, these results indicate that in order to 
develop LFIA for proteins in exosomes, it is necessary to 
consider the relative amounts of the proteins within the 
exosome as well as the multimeric nature of exosomes, 
which can lead to aggregation of AuNP, because several 
epitopes for each antibody are present in each vesicle. 
Thus, this technique requires a careful optimization to 
deal with the possibility of formation of AuNP-exosome 
complexes of different sizes, leading to altered diffu-
sion of the sample and a reduction in the signal detected 
(Fig. 4d).
MICA can be detected using LFIA in human serum
Since it is well established that NKG2D-ligands are found 
in high levels in the serum of different types of cancer 
patients, and the ultimate goal of developing new tools 
for detection of MICA in exosomes is the analysis of bio-
logical fluids, we evaluated the technique replacing run-
ning buffer with increasing amounts of human serum. 
The effect of viscosity from exosome-depleted human 
serum was first evaluated running antibody-only samples 
in the assay. As expected, the baseline signal detected in 
the control line increased. The best results were obtained 
when serum was diluted 1:4 in running buffer (Fig.  5a), 
indicating that the presence of detergent increases the 
fluidity of the sample and increases the signal/noise ratio. 
The titration of melanoma-derived exosomes in serum 
compared to buffer revealed that the signal was higher, 
due to an increase in the background measured in the 
negative control (Fig. 5b, c). Although it is likely that high 
concentration of salts and ions present in sera can cause 
interference [27], these data show that positive signals 
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Fig. 3 Exosomal MICA detected by LFIA from different melanoma cell lines. a Scanned LFIA strips of the exosome titration. Melanoma exosomes 
were derived from either Ma‑Mel‑86c (86c) or Ma‑Mel‑55 (55), incubated with AuNP‑anti‑MICA, as detection antibody, in a final volume of 
100 μL and run for 15 min in triplicates in strips containing a test line of anti‑CD9. Two negative controls were included: a sample containing 
90 × 106 exosomes from the bladder cancer line RT‑112 which does not express detectable MICA and a sample without exosomes (buffer only). 
The positions of the test (T) and control lines (C) are indicated. b Electronic quantitation of the detected signal. The Test line signal from A was 
quantified using the ChemiDoc™ MP Imaging System and represented as arbitrary units (a.u.). Data are the mean and SEM of the triplicates. c 
Comparison of MICA levels by Western blot. The relative amounts of MICA and CD9 expression were checked in the same sample used for LFIA: 
melanoma exosomes derived from Ma‑Mel‑86c (86c), Ma‑Mel‑55 (55) and the bladder cancer cell line RT‑112. Actin was used as loading control. 
d Model proposed. Based on the results of the LFIA experiments comparing exosomes containing different quantities of the detected marker we 
propose a steric hindrance model: if a marker is abundant, the exosome is completely covered by detection antibody. This reduces the availability of 
epitopes for the capture antibody (left panel). However, if the detection marker is more scarce, the exosome can be captured (right panel)
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Fig. 4 Low concentration of antibody in the AuNP increases exosome detection by LFIA. a Scanned LFIA strips. AuNP coupled to decreasing 
amounts of anti‑MICA antibody were prepared and used for detection. Either 50 × 106/µL Ma‑Mel‑86c exosomes (EXO) or no exosomes as control 
(BLANK) were run in strips containing a test line of anti‑CD9. The position of the test (T) and control lines (C) is indicated in figure. b Electronic 
quantitation of the detected signal. Signal in the test line from a was quantified using a ChemiDoc™ MP Imaging System and represented as 
arbitrary units (a.u.). Data represent the mean and SEM of the triplicates. c Hydrodynamic diameter distribution. DLS analysis of AuNP conjugated 
to different amounts of anti‑MICA antibody incubated either alone or with 50 × 106/µL of melanoma‑derived exosomes. The graph shows 
three independent readings of each sample. The value for each peak and the average value (upper right corner) are indicated in the graph. d 
Model of the effect for exosome detection of the antibody concentration coupled to AuNP. When gold nanoparticles are conjugated using high 
concentration of antibody, higher order aggregates are generated due to the crosslinking of antibodies and exosomes. This results in an impaired 
flow of the mixture on the strip and lower capture capacity (left panel). However, if the detection antibody is conjugated at limiting concentration, 
these complexes do not form and each exosome can bind to several AuNP, resulting in better signal detection (right panel)
Page 7 of 12López‑Cobo et al. J Nanobiotechnol  (2018) 16:47 
for similar concentration of exosomes can be detected in 
either serum or buffer-based samples.
Discussion
In this study we have optimized two methods, ELISA and 
LFIA, for the detection in exosomes of MICA, a protein 
released from cancer cells that can affect immune recog-
nition mediated by the activating receptor NKG2D. Both 
techniques have the advantage that they can be used as 
high throughput assays and thus, could be used in clini-
cal studies. Also, both techniques allow detection of two 
different epitopes and so, they prove the co-existence in 
the same vesicle of an exosomal marker and a particular 
antigen. As well as describing the proof-of-concept for 
the simultaneous detection of MICA and tetraspanins in 
exosomes, these data also reveal important differences 
in the use of these techniques for detection of proteins 
in exosomes versus soluble molecules. Further, we have 
identified important features that must be taken into 
consideration when optimising LFIA for exosomal pro-
tein detection to avoid misleading aggregation or steric 
effects. In fact, we demonstrate here that, in LFIA, conju-
gating fewer antibodies per AuNP, unexpectedly, results 
in better sensitivity for exosome detection.
We also demonstrate here for the first time that MICA 
is contained in the same vesicle as the tetraspanins CD9, 
CD63 and CD81. We have previously described that 
MICA*008 can be recruited to exosomes and that it 
migrates in the same sucrose gradient fractions in which 
exosomes were detected (tetraspanin positive fractions 
by Western blot) [20]. We proved that vesicles can be 
captured binding a MICA epitope and this allows detec-
tion of several tetraspanins in the same vesicle. Further, 
we use a model in which MICA protein is expressed 
endogenously in vesicles secreted by melanoma cell lines 
and demonstrate that they are functionally active, down-
modulating the receptor NKG2D on lymphocytes. Thus, 
we have been able to perform an exhaustive characteri-
zation of MICA-containing exosomes that suggests the 
important role that the secretion of these proteins in 
exosomes can have in vivo. The release of MICA-contain-
ing exosomes to serum will depend on the allele present 
in each individual’s genome and it would be desirable to 
perform broader analyses of patients including the detec-
tion of immune modulating exosomes.
It is widely known that any technique used for a new 
purpose requires optimization and here we demonstrate 
that, for detection of proteins on exosomes, the combina-
tion of capture and detection antibodies chosen signifi-
cantly influences the outcome of each method. In ELISA, 
the abundance of an epitope in an exosome does not 
affect binding of the second antibody, because one side 
of the vesicle faces the coated plate leaving the other side 
of the vesicle available for binding. In contrast, in LFIA, 
the abundance of the epitope can impair binding of the 
second antibody, because that first incubation between 
antibody and exosomes occurs in solution, and thus, 
the detection antibody may bind over the entire surface 
of the vesicle (Fig.  6). For this reason, if the detection 
antibody is directed against a very abundant epitope on 
the exosome, steric impediments with the capture anti-
body are more likely to occur. Comparing two types of 
exosomes containing different amounts of MICA, as 
demonstrated by Western blot, our data also prove that 
the amount of the protein detected in exosomes is not 
necessarily linear with respect to the signal obtained. In 
these experiments, it was possible to detect MICA more 
efficiently (higher absolute reading and faster slope and 
saturation curve) when the epitope was less abundant. 
This was also observed when trying different combi-
nations of tetraspanins [25]. Further, steric issues are 
also an important factor to be considered when detect-
ing exosomes by LFIA, since the existence of several 
epitopes in the same vesicle and the coupling of multiple 
detection antibodies per AuNP can result in the forma-
tion of large masses of aggregates. Thus, we recommend 
optimizing coating of detection antibody to AuNP in a 
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Fig. 5 Exosomal MICA detection in human serum by LFIA. a Optimal 
human serum dilution in running buffer. Different volumes of 
exosome‑depleted human serum were run with anti‑MICA detection 
antibody‑conjugated NP, but no exosomes, to identify background 
signal. b Titration of exosomes for MICA detection in human serum by 
LFIA. Melanoma exosomes derived from Ma‑Mel‑55 (55) were tested 
without or with 25% of exosome‑depleted human serum added 
to running buffer (55 + HS). The mixture was run in the strips using 
anti‑CD9 as capture antibody. Scanned strips of the experiment in 
triplicates are shown. The position of the test (T) and control lines (C) 
is indicated in figure. c Quantitation of the detected signal. Signal in 
the test line from B was quantified using the ChemiDoc™ MP imaging 
system and represented as arbitrary units (a.u.). Data represent the 
mean and SEM of the triplicates
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non-saturating concentration range, since the signal can 
be later enhanced by immobilising in the test line a cap-
ture antibody directed against abundant tetraspanins, 
like CD9 in our melanoma cell model.
With the results from this study, we can compare the 
limits for the detection of MICA using ELISA and LFIA. 
However, it is important to stress that, while in ELISA the 
signal obtained is directly proportional to the amount of 
epitopes per exosome, for LFIA, more MICA per exo-
some translated into lower signal, so this technique has to 
be optimized with care for qualitative analysis and com-
plemented with a quantitative technique. In both cases, 
MICA-containing exosomes were easily detected in a 
concentration ranging around 5 × 107 exosome particles 
Fig. 6 Immunocapture of proteins on exosomes requires careful optimization. Although most immunodetection techniques share a common 
basis, i.e. binding with a capture antibody and detection with a complementary antibody, the methodological procedure affects the ability of a 
reagent to bind to the sample. In ELISA, incubation with the detection antibody is done after capture of exosomes on the antibody‑coated plated 
while, in LFIA, exosomes are mixed in solution with the antibody. Thus, in ELISA, one side of the exosome is available for binding while, in LFIA, the 
exosome can be completely recovered by detection antibody. As a consequence, in ELISA, more detection antibody bound to the exosome results 
in a higher signal while in LFIA, more detection antibody, results in steric hindrance and the impossibility of being captured
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per μl. The last aspects to compare on the two techniques 
used here are the time consumed for assay implementa-
tion and price per sample analysed; as usual, LFIA is fast 
and relatively cheaper than ELISA. Thus, depending on 
the final application either method can be of great inter-
est to implement for either basic or clinical research of 
exosomal surface proteins.
It is widely known that the presence of plasma can 
increase the background noise in ELISA. Thus, we evalu-
ated the effect of plasma when making the measurements 
by LFIA. As in other methods, plasma increased the sig-
nal in control samples, however, positive samples also 
had a clear increase. Thus, we can anticipate that LFIA 
could be used to evaluate the presence of particular pro-
teins in exosomes from patient samples.
The requirement of non-abundant epitopes for detec-
tion represents an advantage for LFIA; tumour-derived 
antigens are, in general, much less abundant than tet-
raspanins in exosomes [3] and, in biological fluids, 
tumour-derived exosomes are expected to be a minority 
in plasma, since they will be mixed with exosomes from 
healthy cells. This technique permits the enrichment of 
tumour derived-exosomes and enhanced visualization 
with an abundant tetraspanin marker.
In conclusion, in this paper we have described the detec-
tion of the non-abundant tumour-derived antigen MICA 
in exosomes using two immunodetection-based methods 
and we describe the different parameters that require care-
ful optimization for the implementation of new exosome 
markers. Strikingly, antibody coating of AuNP needs to be 
titrated down for a better detection in LFIA.
Methods
Reagents and cells
Reagents were purchased from sigma, unless otherwise 
stated.
The human metastatic melanoma cell lines Ma-Mel-55 
and Ma-Mel-86c were previously described [26], and 
genotyped for MICA. Both cell lines only express MICA 
A5.1, which is recruited to exosomes. Cells were grown in 
RPMI-1640 supplemented with 10% FCS, 1 mM glutamine, 
1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
10 mM Hepes, 100 U/mL penicillin and 100 U/mL strep-
tomycin (Biowest). The bladder cancer cell line RT-112 is 
available from the ATCC [kindly provided by Dr. FX Real 
(CNIO, Madrid) and genotyped using the StemElite ID Sys-
tem (Promega) at the Genomics Service (IIB-CSIC)]. These 
cells were grown in EMEM medium (Lonza) supplemented 
with 10% FCS, 1 mM glutamine, 1  mM sodium pyruvate, 
0.1  mM non-essential amino acids, 100  U/mL penicillin, 
and 100 U/mL streptomycin (Biowest).
Peripheral blood mononuclear cells (PBMC) were 
purified from healthy volunteer buffy coats (Regional 
Transfusion Centre, Madrid). Approval from local ethical 
committees (Transfusion Centre and CSIC) and informed 
consent from all participants were obtained. After Ficoll 
isolation, PBMCs were stimulated with 10  U/mL IL-12 
(Peprotech) and 25 mg/mL IL-18 (MBL) to allow enrich-
ment of the Natural Killer (NK) cell population. Buffy coats 
(Regional Transfusion Centre, Madrid) were used under 
approval from local ethical committees (Transfusion Cen-
tre and CSIC) and informed consent from all participants.
Exosome isolation, quantitation and EM visualization
For exosome enrichment, cells were cultured for 
3–5 days in their appropriate medium, but with 1% exo-
some-free FCS (prepared by centrifugation at 100,000×g 
for 18  h and sterile-filtered). Cell culture supernatants 
were centrifuged for 10 min at 200×g to discard cells and 
exosomes were purified by sequential centrifugation as 
previously described [20, 21]. Briefly, supernatants were 
centrifuged for 10  min at 500×g, 30  min at 10,000×g 
and finally ultracentrifuged at 100,000×g for 2 h at 4  °C 
(Beckman Instruments). The pellet, containing exosomes, 
was resuspended in HEPES-buffered saline buffer (HBS: 
10 mM HEPES pH 7.2, 150 mM NaCl). For liophylization 
the buffer was supplemented with 8% sucrose, samples 
were frozen immediately at − 80 °C and lyophilized using 
a Flexi-Dry Lyophilizer (FTS Systems).
Exosome concentration was determined by nanoparti-
cle tracking analysis (NTA) in a NanoSight NS500 (Mal-
vern Instruments Ltd, Malvern, UK). A 405-nm laser 
beam was used to highlight the particles, which act as 
point scatters. Analysis was performed using the NTA 
3.1 software (Malvern). These experiments were carried 
out at the laboratory of Dr. H. Peinado, Spanish National 
Centre for Oncological Research (CNIO). Electron 
microscope examination of exosomes was carried out as 
previously described [25].
Western blot
The same number of purified exosomes (7 × 109) resus-
pended in Laemmli buffer (non-reducing condition for 
tetraspanins) was run on 12% SDS-PAGE gels. Samples 
were transferred to Immobilon-P (Millipore) membrane. 
The membrane was blocked using PBS containing 0.1% 
Tween-20 (PBS-T) and 5% non-fat dry milk. The tetras-
panins, CD63, CD9 and CD81, were detected by incuba-
tion with MEM-63, MEM-9 and MEM-81, respectively 
[kind gift from Vaclav Horejsi (Czech Republic)]. For 
MICA detection, the membrane was incubated with 
biotinylated goat polyclonal anti-MICA antibody (R&D) 
(BAF1300). Mouse anti- β-actin (AC-15) was from 
Sigma. The secondary antibody goat anti-mouse Ig-HRP 
(Dako) or streptavidin-HRP (Biolegend) were used before 
developing using the ECL system (GE Pharmaceuticals).
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NKG2D downmodulation
The day before the experiments, PBMC were stimulated 
with 20 ng/mL IL-15 (Peprotech) for 18 h. The percent-
age of NK cells in PBMC cultures was assessed by flow 
cytometry using CD3 and CD56-specific mAbs. PBMC 
 (105 NK cells) were incubated in 96-well flat-bottomed 
plates with 1–5 × 1010 melanoma-derived exosomes (or 
with exosome-free RPMI medium, as negative control). 
After 24 h, NKG2D surface expression on NK cells was 
monitored by staining with PE-conjugated anti-NKG2D 
antibody, FITC-anti-CD3 (BioLegend) and APC-anti-
CD56 (e-Bioscience), and flow cytometry analysis using 
the cytometer Cytomics FC 500 (Beckman Coulter) and 
Kaluza (Beckman Coulter) software.
ELISA
MICA and tetraspanins were detected in melanoma-derived 
exosomes using sandwich ELISA. Plates were coated with 
purified mAb R&D against MICA (MAB13002) or anti-
tetraspanin antibodies (anti-CD9 VJ1/20 [28] or anti-CD63 
Tea3/18 [29] in BBS (Borate Buffered saline) overnight at 
4 °C. After blocking the plates with 2% BSA-HBS for 2 h at 
37  °C, melanoma-derived exosomes were added (or HBS 
as negative control) and incubated overnight at 4 °C. Bioti-
nylated secondary antibodies [CD9 VJ1/20 [25] and MICA 
(BAF1300, R&D)] were added and followed by streptavi-
din-HRP (Amersham). The reaction was developed using 
the peroxidase substrate system (ABTS; Roche). Absorb-
ance was measured at 405 nm with a reference wavelength 
of 490 nm with Thermo Scientific™ Multiskan™ FC Filter-
based Microplate Photometer (Thermo Fisher Scientific).
Size distribution
Size distribution was measured with a Zetasizer Nano ZS 
ZEN3600 (Malvern Instruments, Malvern, UK). The samples 
were diluted (50- to 100-fold) fractions and 3 readings were 
performed. Each reading was composed of 15 measurements 
of the backscattered (173°) intensity. Zetasizer software ver-
sion 7.03 was used for data processing and analysis.
Lateral flow immunoassay
The LFIA was carried out in a dipstick format as described 
in [25]. Capture antibodies [anti-MICA (1H10), anti-
CD63 (Tea3/18), anti-CD81 (5A6, provided by Dr. S. Levy, 
Department of Oncology, Stanford University School of 
Medicine, Stanford, CA), anti-CD9 (VJ1/20, Immunostep)] 
and control anti-IgG antibody were loaded onto a nitrocel-
lulose membrane to make a test and a control line in the 
strip, using a dispenser IsoFlow (Imagene Technology, 
USA) at a flow rate of 0.100 µL/mm. For trial experiments, 
the lines were prepared manually, dispensing 3 × 0.3 µL of 
the corresponding antibody (1  mg/mL). The membrane 
was dried for 20 min at 37 °C.
Detection antibodies [anti-CD9 (VJ1/20), anti-CD63 
(Tea3/18), anti-MICA (1H10, [30] or MAB13002 from 
R&D)] were conjugated to 40  nm gold nanoparticles 
(AuNP) from BB International (UK). A gold colloid titration 
was done to estimate the optimal concentration of the anti-
body to stabilize the gold nanoparticles [31]. For anti-CD63 
and anti-MICA labelling, a non-covalent bioconjugation 
protocol was followed, while a covalent procedure was nec-
essary for anti-CD9, protocols previously described in [25].
Purified exosomes were prepared in running buffer 
(10  mM HEPES, pH 7.4, with 150  mM NaCl, 0.05% 
Tween-20 and 1% BSA) and transferred to a microtube 
containing 20 µL of antibody-coupled AuNP (in the exper-
iments shown in Additional file 1: Figure 1A and B, 10 µL) 
in a final volume of 100  µL. For negative control, buffer 
without exosomes was added to the detection antibody. 
For most of the experiments, a pre-incubation of 1 h was 
used prior to introduction of the dipstick in the microtube 
for a run of the LFIA of 15 min. 100 µL of running buffer 
were added after the sample. When other pre-incubation 
times were used, it is indicated in figure legend.
After the run, the signal obtained in the test line was quan-
titated by scanning the strips using ChemiDoc™ MP Imaging 
System and analyzing with Image Lab Software (Bio-Rad).
Stastistical analysis
Student’s t-test was done for paired samples using Graph-
Pad Prism 5. P-values are shown in each figure; only sig-
nificant differences are indicated.
Additional file
Additional file 1: Figure S1. Optimization of LFIA for exosomal MICA 
detection. A. Antibodies combination. Different antibody combinations 
for capture and detection, as indicated, were tried. B. Running buffer 
composition. The addition of different concentrations of Tween 20 and 
ethanol with anti‑MICA in the running buffer was tested. In A and B, the 
amount of antibody‑coupled AuNP was 10 µL, thus, for comparison, the 
same set of strips was used in the no ethanol (0% ethanol) and 10 µL of 
detection antibody sets. C. Incubation time. Melanoma exosomes were 
incubated with the detection antibody anti‑MICA conjugated to AuNP 
for different times prior to the run on the strip. D. Effect of including two 
steps for dispensing exosomes and antibody‑coupled NP to the LFIA strip. 
Exosomes were incubated with detection anti‑MICA antibody NP and dis‑
pensed to the dipstick in one step. Alternatively, exosomes were run first 
and, in a second step, the detection antibody‑coupled NP. The test strips 
in triplicates are shown. Right graph: quantitation of the test line signal 
represented as arbitrary units (a.u.). Data are the mean and SEM of the 
triplicates. The capture antibodies were immobilized manually in the strips 
and exosomes were not pre‑incubated with detection antibody for one 
hour in A and B. In B, C and D, anti‑CD9 was used as capture antibody and 
anti‑MICA‑NP for detection. Melanoma exosomes derived from Ma‑Mel‑55 
(55) or Ma‑Mel‑86c (86c) were run (E, EXO) or no exosomes as control (B, 
BLANK). The position of the test (T) and control lines (C) are depicted. 
Figure S2. Visual analysis of the sample pads colour. Pads from the experi‑
ments above were scanned to appreciate the material still embedded in 
the pad at the end of the running time. A. Effect of incubation time. Pads 
from the experiments shown in Additional Figure 1C. B. Titration of exo‑
some concentration. Pads from the experiments shown in Figure 4B.
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